Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cellsDaniel A. Lichtenstein, Nirali N. Shah, Yanyu Wang et al.|Blood|2021Cited by 194
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapyElizabeth M. Holland, Nirali N. Shah, Bonnie Yates et al.|Blood Advances|2021Cited by 67
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicityJennifer Jess, Nirali N. Shah, Bonnie Yates et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 35